Age and HIV stage at initiation of highly active antiretroviral therapy determine non-reversal of stunting at 3 years of treatment

Main Article Content

Putu Diah Vedaswari
Ketut Dewi Kumara Wati
I Gusti Lanang Sidiartha
I Gusti Ayu Putu Eka Pratiwi
Hendra Santoso
Komang Ayu Witarini

Abstract

Background Highly active antiretroviral therapy (HAART) has been reported to improve growth, especially in the first 2 years of treatment. It is not clear whether catch up growth is maintained after 2 years of HAART.


Objective To assess growth in stunted children with HIV after 3 years of HAART and analyze possible risk factors for non-reversal of stunting.


Methods This study was done from May 2016 to April 2017 to follow children with HIV who started HAART between January 2009 and April 2014, and continued for 3 years. Inclusion criteria were children with HIV, aged < 18 years, compliance to the regimen, and stunting. Exclusion criteria were patients lost to follow up or who died prior to 3 years of HAART. Non-reversal of stunting was defined as HAZ ≤ -2SD after 3 years of HAART. Possible risk factors for non-reversal were analyzed using Chi-square test with P<0.05, as well as risk ratio (RR) and 95% confidence intervals (CI).


Results Of 150 HIV-infected pediatric patients, 115 were on HAART and 55 (47.8%) were stunted at HAART initiation. Of the 55 stunted and HAART-treated children, 31 (56.4%) were male. Baseline median age was 3.6 years (interquartile range 0.37-8.48). Non-reversal occurred in 32 (58.2%) subjects. Multivariate Cox regression model analysis showed predictors of non-reversal after 3 years of HAART to be age >2 years (RR 16.05; 95%CI 2.89 to 89.02; P=0.002) and HIV stage III-IV (RR 8.93; 95%CI 1.47 to 54.37; P=0.017).


Conclusion HAART initiation at age >2 years and HIV clinical stage III-IV at diagnosis are risk factors for non-reversal of stunting after 3 years of HAART.

Article Details

How to Cite
1.
Vedaswari P, Wati K, Sidiartha IG, Pratiwi IG, Santoso H, Witarini K. Age and HIV stage at initiation of highly active antiretroviral therapy determine non-reversal of stunting at 3 years of treatment. PI [Internet]. 30Aug.2018 [cited 22Nov.2018];58(4):180-. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/1807
Section
Infection & Tropical Pediatrics

References

1. Setiawan IM. Tatalaksana pencegahan penularan vertikal dari ibu terinfeksi HIV ke bayi yang dilahirkan. Maj Kedokt Indon. 2009;59:488-99.
2. Kemenkes RI. 2012. Profil kesehatan Indonesia 2012. Jakarta: Kementerian Kesehatan Republik Indonesia; 2013.
3. Ditjen PP dan PL Kemenkes RI. Statistik kasus HIV/AIDS di Indonesia, 2014; [cited 2017 May 29]. Available from: http: www.spiritia.or.id/Stats/StatCurr.pdf.
4. WHO. Global update on the health sector response to HIV, 2014; [cited 2017 May 28] Available from: http://www.who.int/hiv/pub/progress_report2011/en/.
5. Lee GM, Gortmaker SL, McIntosh K, Hughes MD, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219C Team. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics. 2006;117:273-83.
6. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access recommendations for a public health approach. 2010 revision. Austria: WHO Library Cataloguing-in-Publication Data; 2010. p. 1-5.
7. Mwiru RS, Spiegelman D, Duggan C, Seage III GR, Semu H, Chalamilla G, et al. Growth among HIV-infected children receiving antiretroviral therapy in Dar es Salaam, Tanzania. J Trop Pediatr. 2014;60:179-88.
8. Suryani IGAA, Wati KDK, Sidiartha IGL. Nutritional status improvement of child with HIV-1 infection within 12 months highly active antiretroviral therapy in Sanglah Hospital Denpasar. Medicina. 2017;48:93-7.
9. Sari LS, Wati KDK, Sidiartha IGL. Growth recovery of children with infection at 24 months highly active antiretroviral therapy at Sanglah Hospital Denpasar. Medicina. 2021;52:1-10.
10. Shiau S, Arpadi S, Strehlau R, Martens L, Patel F, Coovadia A, et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013;162:1138-45.
11. Bunuparadah T, Kariminia A, Aurpibul L, Chokephaibulkit K, Hansudewechakul R, Lumbiganon P, et al. Final height and associated factors in perinatally HIV-infected Asian adolescents. Pediatr Infect Dis J. 2016;35:201-4.
12. Aurpibul L, Puthanakit, T, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Aids Patient Care STDS. 2009;23:1067-71.
13. WHO. Nutrition landscape information system (NLIS) country profile indicators: interpretation guide. Switzerland: WHO Press; 2010.
14. Sunguya BF, Poudel KC, Otsuka K, Yasuoka J, Mlunde LB, Urassa DP, et al. Undernutrition among HIV-positive children in Dar es Salaam, Tanzania: antiretroviral therapy alone is not enough. BMC Public Health. 2011;11:869.
15. WHO. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Switzerland: WHO Press; 2006. p. 16-17.
16. Waterlow JC, Buzina R, Keller W, Lane JM, Nichaman MZ, Tanner JM. The presentation and use of height and weight data for comparing the nutritional status of groups of children under the age of 10 years. Bull World Health Organ. 1977;55:489-98.
17. Lang T. Documenting research in scientific articles: Guidelines for authors: 3. Reporting multivariate analyses. Chest. 2007;131:628-32.
18. McDonald CM, Kupka R, Manji KP, Okuma J, Bosch RJ, Aboud S, et al. Predictors of stunting, wasting, and underweight among Tanzanian children born to HIV-infected women. Eur J Clin Nutr. 2012;66:1265–76.
19. Prendergast AJ, Humphrey JH. The stunting syndrome in developing countries. Paediatr Intl Child Health. 2014;34:250-65.
20. Prendergast AJ, Rukobo S, Chasekwa B, Mutasa K, Ntozini R, Mbuya MNN, et al. Stunting is characterized by chronic inflammation in Zimbabwean infants. PLoS One. 2014;9:e86928.
21. Weigel R, Phiri S, Chiputula F, Gumulira J, Brinkhof M, Gsponer T, et al. Growth response to antiretroviral treatment in HIV-infected children: a cohort study from Lilongwe, Malawi. Trop Med Int Health. 2010;15:934-44.
22. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious disease clinic in Uganda. AIDS Patient Care STDS. 2008;22:245-51.
23. Sutcliffe CG, van Dijk JH, Munsanje B, Hamangaba F, Sinywimaanzi P, Thurna PE, et al. Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study. BMC Infect Dis. 2011;11:54.
24. McGrath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart GC. Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS. 2011;25:345-55.
25. Diniz LM, Maia MM, Camargos LS, Amaral LC, Goulart EM, Pinto JA. Impact of HAART on growth and hospitalization rates among HIV-infected children. J Pediatr (Rio J). 2011;87:131-7.
26. Huy BV, Teeraananchai S, Oanh LN, Tucker J, Kurniati N, Hansudewechakul R, et al. Impact of orphan status on HIV treatment outcomes and retention in care of children and adolescents in Asia. J Virus Erad. 2016;2:227-31.